Raynaud’s and Chilblains: Understanding the Causes — and When to Look Deeper

Raynauds, autoimmune disease, chilblains, private rheumatologist

Cold, painful fingers or toes are common in winter, but for some people these symptoms are more than simple cold sensitivity. Raynaud’s phenomenon and chilblains are two conditions frequently encountered in rheumatology practice. While they can overlap, they have different mechanisms, implications and management strategies. Understanding the difference — and knowing when further assessment is needed — is key.

What Is Raynaud’s Phenomenon?

Raynaud’s phenomenon occurs when small blood vessels in the fingers or toes constrict excessively in response to cold or emotional stress. This leads to characteristic colour changes:

  • White – reduced blood flow

  • Blue – prolonged lack of oxygen

  • Red – blood returning to the tissues

Symptoms may include numbness, tingling, throbbing or pain and usually improve with rewarming.

Primary vs Secondary Raynaud’s

Distinguishing between primary and secondary Raynaud’s is one of the most important aspects of assessment.

Primary Raynaud’s

  • Very common

  • Often begins in adolescence or early adulthood

  • No underlying disease

  • Normal blood tests

  • Usually symmetrical and relatively mild

  • No tissue damage

Primary Raynaud’s is uncomfortable but not dangerous, and many patients manage well with lifestyle measures alone.

Secondary Raynaud’s: When There Is an Underlying Cause

Secondary Raynaud’s occurs as part of another condition and is clinically more significant. It may be associated with:

Connective tissue and autoimmune diseases

  • Systemic sclerosis (scleroderma)

  • Lupus

  • Sjögren’s syndrome

  • Inflammatory myositis

  • Mixed connective tissue disease

Vascular and blood-related causes

  • Vasculitis

  • Cryoglobulinaemia

  • Antiphospholipid syndrome

Mechanical or occupational factors

  • Repeated vibration exposure

  • Thoracic outlet syndrome

Medications

  • Beta blockers

  • Certain migraine therapies

  • Chemotherapy agents

Smoking

  • A major contributor due to powerful vasoconstriction

Red flags suggesting secondary Raynaud’s include later onset, severe pain, asymmetry, ulcers, slow healing, or associated symptoms such as joint pain, rashes, fatigue or breathlessness.

What Are Chilblains?

Chilblains (also known as pernio) are inflammatory skin lesions that develop after exposure to cold and damp conditions. They typically appear as:

  • Red or purple patches

  • Swollen, tender or itchy areas

  • Commonly affecting toes, fingers, ears or the nose

Unlike Raynaud’s, chilblains are caused by inflammation and leakage of small blood vessels, rather than transient spasm alone. Lesions may take days to weeks to settle.

Chilblains can occur in isolation or alongside Raynaud’s and are more common in people with poor circulation, low body weight, prolonged cold exposure, or underlying autoimmune disease.

Chilblains and “COVID Toes”

During the COVID-19 pandemic, a form of chilblain-like lesions became widely recognised, often referred to as “COVID toes.” These lesions typically present as red or purple, swollen, sometimes painful patches on the toes (and occasionally fingers), and may resemble classical chilblains.

Key features include:

  • Occurring during or shortly after COVID-19 infection

  • Often seen in younger patients and children

  • May appear even in the absence of cold exposure

  • Usually self-limiting

The exact mechanism is not fully understood but is thought to involve immune-mediated inflammation of small blood vessels, rather than direct viral damage. Importantly, COVID-related chilblain-like lesions generally resolve on their own and do not usually indicate long-term vascular disease.

However, persistent, recurrent or atypical chilblains — particularly outside winter months — still warrant assessment to exclude underlying autoimmune or inflammatory conditions.

Assessment: Looking Beyond the Skin

When assessing Raynaud’s or chilblains, I take a whole-person, systematic approach, including:

  • Age of onset and symptom pattern

  • Severity and triggers

  • Examination of skin, nails and joints

  • Nailfold capillaroscopy where appropriate

  • Autoimmune blood tests

  • Inflammatory markers

  • Review of medications and lifestyle factors

This approach helps distinguish benign conditions from those requiring closer monitoring or treatment.

Management: What Helps?

Lifestyle measures

  • Keeping the whole body warm

  • Layered clothing

  • Gloves even in mild cold

  • Avoiding rapid temperature changes

  • Smoking cessation

These measures are essential and often highly effective.

Medications

For more severe symptoms or secondary causes:

  • Vasodilator therapies

  • Treatment of underlying autoimmune disease

  • Targeted therapy for ulcers or complications

Supplements in Primary Raynaud’s

In selected patients with primary Raynaud’s, supplements may provide modest benefit as part of a broader strategy. These are not a replacement for medical treatment, but may help some individuals.

Commonly discussed options include:

  • Omega-3 fatty acids

  • Magnesium

  • L-arginine

Use should be individualised and reviewed to avoid interactions or false expectations.

Why Specialist Assessment Matters

Raynaud’s and chilblains sit at the intersection of vascular, inflammatory and autoimmune medicine. While many cases are benign, some represent early signs of systemic autoimmune disease.

Patients often value:

  • Clear explanations

  • Reassurance without dismissal

  • Understanding what to monitor

  • A structured plan

Early assessment provides clarity, confidence and — where needed — timely intervention.

In Summary

  • Raynaud’s and chilblains are common, particularly in colder months

  • Primary Raynaud’s is usually benign

  • Secondary Raynaud’s requires careful evaluation

  • Chilblains may occur after COVID-19 infection

  • Supplements may help selected patients with primary Raynaud’s

  • A whole-person approach ensures appropriate reassurance and investigation

Dr Animesh Singh, Consultant Rheumatologist. GMC: 6130215


Please note, these posts are for general information only and do not constitute medical advice. Dr Singh would encourage you to speak to your healthcare professional to be assessed and managed for your specific symptoms.

Previous
Previous

Romosozumab (Evenity®) in Osteoporosis: When and Why It Is Used

Next
Next

Understanding Bone Health and Osteoporosis: What Patients Should Know